PMID: 11927845Apr 3, 2002Paper

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

Retina
Eyetech Study Group

Abstract

Recent studies have suggested that vascular endothelial growth factor (VEGF) is an important stimulus for the growth of new blood vessels in the eye. Anti-VEGF therapy is thus a potential treatment for exudative macular degeneration and diabetic retinopathy. Previously described animal models of vascular leakage and ocular neovascularization, including the Miles assay, the rat corneal angiogenesis model, and the mouse retinopathy of prematurity (ROP) model, were used to study this drug. After these studies, a phase IA single ascending dose study of intravitreal injections of the drug was performed in 15 patients with subfoveal choroidal neovascularization secondary to exudative age-related macular degeneration (AMD). The Miles assay model showed almost complete attenuation of VEGF-mediated vascular leakage following addition of EYE001, and the corneal angiogenesis model also showed a significant reduction in neovascularization with EYE001. The ROP model showed inhibition of 80% of the retinal neovascularization compared with controls (P = 0.0001). The phase IA safety study of patients with exudative AMD showed no significant safety issues related to the drug. Ophthalmic evaluation revealed that 80% of patients showed stable or ...Continue Reading

Associated Clinical Trials

Mar 5, 2012·David M. Brown, M.D., David M. Brown, M.D.

References

Apr 1, 1983·The British Journal of Ophthalmology·I M GhafourW S Foulds
Nov 7, 1995·Proceedings of the National Academy of Sciences of the United States of America·L P AielloL E Smith
Oct 12, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·C E TuckerD W Drolet

❮ Previous
Next ❯

Citations

Nov 12, 2005·Applied Microbiology and Biotechnology·Daniela ProskeAnsgar Resch
Jul 20, 2004·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Faik GeliskenKarl Ulrich Bartz-Schmidt
May 21, 2005·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·J Fernando ArevaloAristides J Mendoza
Dec 23, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·S AisenbreyK U Bartz-Schmidt
Mar 3, 2007·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Rogério A CostaIngrid U Scott
Jan 15, 2005·Pharmaceutical Research·Judith M HealyThomas G McCauley
Mar 7, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Amol D Kulkarni, Michael S Ip
Jun 21, 2005·Biochimie·C PestourieF Duconge
Oct 25, 2003·Progress in Retinal and Eye Research·Arup Das, Paul G McGuire
May 15, 2003·Survey of Ophthalmology·Jayakrishna AmbatiAnthony P Adamis
Oct 16, 2004·Optometry : Journal of the American Optometric Association·Megan A HunterPhillip J Rosenfeld
May 16, 2003·Vascular Pharmacology·Geerten P van Nieuw Amerongen, Victor W M van Hinsbergh
Apr 7, 2012·Molecular Pharmaceutics·Victoria L ElliottNeil R Kitteringham
Jul 11, 2006·Nature Biotechnology·Roger G FahmyLevon M Khachigian
Oct 6, 2009·Nature Medicine·Sabah OneyBruce A Sullenger
Mar 7, 2006·Nature Reviews. Drug Discovery·Eugene W M NgAnthony P Adamis
Sep 7, 2012·Chemical Communications : Chem Comm·Guizhi ZhuWeihong Tan
Jan 2, 2004·The New England Journal of Medicine·Robert N Frank
Jul 29, 2004·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Mohammed El BradeyWilliam R Freeman
Mar 1, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ozcan R KayikciogluWilliam R Freeman
Nov 2, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jost B JonasFrank Schlichtenbrede
Mar 17, 2009·Oligonucleotides·Charlene M BlakeYolanda M Fortenberry
Dec 4, 2004·International Ophthalmology Clinics·Rubin W Kim, Jeffrey S Heier
Dec 4, 2004·International Ophthalmology Clinics·Matthew J Thompson, Michael S Ip
Oct 20, 2004·Retina·Rama D JagerEmmett T Cunningham
Feb 4, 2005·Retina·Anthony P Adamis, David T Shima
Sep 12, 2006·Retina·Christina M KlaisLawrence A Yannuzzi
Oct 25, 2006·International Ophthalmology Clinics·Barrett Katz, Mauro Goldbaum
Jan 16, 2007·Retina·Ingrid U Scott, Harry W Flynn
Jul 9, 2009·Retina·Gholam A PeymanDarius M Moshfeghi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.